
First-Line Camizestrant for Emerging - The New England Journal of …
Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced …
A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus ...
Jun 12, 2025 · Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. In an open-label, two-period, two-sequence, cross ...
Survival of Transplanted Allogeneic Beta Cells with No ...
Aug 4, 2025 · The need to suppress a patient’s immune system after the transplantation of allogeneic cells is associated with wide-ranging side effects. We report the outcomes of transplantation of ...
Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis
Mar 5, 2025 · Bacterial vaginosis affects one third of reproductive-aged women, and recurrence is common. Evidence of sexual exchange of bacterial vaginosis–associated organisms between …
Lorundrostat Efficacy and Safety in Patients with Uncontrolled ...
Apr 23, 2025 · Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this …
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured …
Clinical Practice Topics | The New England Journal of Medicine
Recognizing Historical Injustices in Medicine and the Journal Tobacco Use Reduction Additional Topics A Accountable Care Organizations Acute Coronary Syndromes Acute Kidney Injury Addiction
Zongertinib in Previously Treated - The New England Journal of Medicine
Apr 28, 2025 · Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is an oral ...
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Apr 8, 2025 · Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple …
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous ...
Jun 22, 2025 · In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. A fixed-dose regimen of insulin efsitora alfa...